AbGn-107

N/A

Report date: 2024/02/05 13:57:30

Base Information

Drug NameAbGn-107

Drug Alias NameAbGn-107

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Dolastatin analogue payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAltrubio Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbgenomics B.V Taiwan Branch

Active IndicationsN/A

Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4]

Other Information

ATC CodeN/A